Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of two drugs, SHR-A2102 and Adebali monoclonal antibody injection, indicating progress in its oncology pipeline [1] Group 1: Drug Development - The company’s subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has been authorized to conduct clinical trials for SHR-A2102, a targeted antibody-drug conjugate (ADC) that specifically targets Nectin-4, which is associated with tumor progression and poor prognosis [1] - SHR-A2102 contains a topoisomerase I inhibitor as its effective payload, highlighting its potential in cancer treatment [1] - Adebali monoclonal antibody injection, a humanized anti-PD-L1 monoclonal antibody developed by the company, has already been approved for use in combination with carboplatin and etoposide for first-line treatment of extensive-stage small cell lung cancer [1] Group 2: Market Position - The approval of Adebali monoclonal antibody injection in March 2023 marks a significant milestone for the company, enhancing its position in the oncology market [1] - The company is actively expanding its oncology portfolio, which may lead to increased market share and revenue growth in the future [1]